Koyfin Home > Directory > Health Care > Arena Pharmaceuticals > EBITDA / Interest Expenses

Arena Pharmaceuticals EBITDA / Interest Expenses Chart (ARNA)

Arena Pharmaceuticals annual/quarterly EBITDA / Interest Expenses from 2012 to 2016. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Arena Pharmaceuticals EBITDA / Interest Expenses for the quarter ending December 12, 2016 was $39m
  • Arena Pharmaceuticals EBITDA / Interest Expenses for the last 12 months ending September 09, 2017 was $1m a 2.20% increase of 0m year over year
Other Ratios Metrics:
  • Arena Pharmaceuticals Total Debt / Capital for the quarter ending September 09, 2018 was $10m a -127.22% decrease of -13m year over year
  • Arena Pharmaceuticals Other Liabilities for the quarter ending September 09, 2018 was $1m a -69.22% decrease of -1m year over year
  • Arena Pharmaceuticals Total Debt / Equity for the quarter ending September 09, 2018 was $11m a -165.14% decrease of -19m year over year
View Chart On Koyfin

Quarterly ARNA EBITDA / Interest Expenses Data

12/2016$39m
06/2013$24m
06/2012$2m

Annual ARNA EBITDA / Interest Expenses Data

2016$3m